Abstract
Acute rhinosinusitis and chronic rhinosinusitis are inflammatory diseases of the mucosal membranes due to mislead immunological reactions to aeroallergens. T‑cells are divided into different groups based on their cytokine secretion: T‑helper type 1 (Th1) and type 2 (Th2) cells. The allergic immune response is caused by activation of specific Th2 cells. With specific immunotherapy, the mislead hyperactivated “allergic” immune response is reduced to a reaction within the normal range. The inflammatory forms of chronic rhinosinusitis are called endotypes, and, in the future, could enable a targeted, pathomechanistic therapy. These endotype-based treatment approaches target specific signaling pathways that have already shown good effects for chronic rhinosinusitis with nasal polyps using monoclonal antibodies. However, so far, only selected patients with non-rhinologic indications, off-label treatments, or in clinical trials have benefited from these treatments.
Translated title of the contribution | T-cell immune responses in chronic inflammatory diseases of the nasal mucosa |
---|---|
Original language | German |
Journal | HNO |
Volume | 67 |
Issue number | 11 |
Pages (from-to) | 881-892 |
Number of pages | 12 |
ISSN | 0017-6192 |
DOIs | |
Publication status | Published - 01.11.2019 |
Research Areas and Centers
- Research Area: Luebeck Integrated Oncology Network (LION)